Reumatólogos frente al papeleo: evaluación de la carga administrativa en un Servicio de Reumatología / Rheumatologists versus paperwork: assessment of administrative burden in a Rheumatology Service

Introducción: los resúmenes de historia clínica (RHC), confeccionados por reumatólogos, los solicitan los pacientes para realizar diversos trámites. Su incumplimiento afecta el acceso a las prestaciones sanitarias e implica que los médicos destinen tiempo a un requisito puramente burocrático. Los objetivos de este estudio fueron: determinar la frecuencia de RHC solicitados y realizados en nuestro Servicio durante un semestre y el tiempo dedicado a dicha tarea; describir los motivos de las solicitudes y las características de los solicitantes. Materiales y métodos: se incluyeron todos los pacientes que solicitaron ≥1 RHC en el último semestre de 2019. Se registraron características sociodemográficas, enfermedad de base y motivos de solicitud. Se consideró, como parámetro de comparación, una duración predeterminada de 15 minutos por consulta médica. Resultados: se registraron 103 solicitantes de RHC en 3159 citas programadas en 152 días. Se realizaron 144 RHC (0,95/día). Un 18% solicitó uno nuevo en el mismo intervalo. El tiempo promedio para la confección de cada resumen fue de 75 minutos. El tiempo total dedicado a estas tareas administrativas en el semestre evaluado fue el equivalente a 720 citas potenciales, aproximadamente un 20% de los turnos programados ofrecidos. La mayoría se emitió para solicitar medicamentos crónicos, principalmente para artritis reumatoidea, y con cobertura médica pública. Conclusiones: el tiempo destinado a confeccionar RHC por motivos administrativos fue el equivalente a un aumento potencial de más del 20% de las citas médicas.

Introduction: medical history summaries (MHS) issued by rheumatologists are requested by patients for various procedures. Not completing them denies access to health benefits, this implies that physicians spend time on a purely bureaucratic requirement. The objectives were: to determine the frequency of MHS requested and issued in our service during a semester and the time dedicated to them; to describe the reasons for the request and the characteristics of the applicants. Materials and methods: all patients who request ≥1 MHS in the last semester of 2019 were included. Sociodemographic characteristics, underlying disease and reasons for request were recorded. As a comparison measure, a predetermined duration of 15 minutes per medical appointment was expected. Results: 103 MHS applicants in 3159 scheduled appointments in 152 days. 144 MHS were performed (0.95/day). 18% requested a new one in the same interval. The average time in the preparation of a MHS was 75 minutes. The total time spent on these during the evaluated semester was equivalent to 720 potential appointments, approximately 20% of scheduled appointments that were granted. Most were issued to request chronic medications, mainly in rheumatoid arthritis and public health care. Conclusions: the time spent to prepare MHS for administrative reasons was comparable to a potential increase of more than 20% in medical appointments.

Impacto de la pandemia por SARS-CoV-2 en la formación de los alumnos de la Carrera de Médico Especialista en Reumatología / Impact of the SARS-CoV-2 pandemic on a group of Rheumatology trainees of Argentina

Introducción: en 2020, la rápida evolución de la pandemia por SARS-CoV-2 desencadenó una emergencia sanitaria que generó una importante reorganización del sistema de salud, lo que llevó a la discontinuación y posterior adecuación de los sistemas de formación. El objetivo de este estudio fue describir el impacto de la pandemia en un grupo de reumatólogos en formación en la Ciudad Autónoma de Buenos Aires. Materiales y métodos: se envió una encuesta online por correo electrónico a los alumnos de la Carrera de Especialista en Reumatología de la Sociedad Argentina de Reumatología y de la Universidad de Buenos Aires. Incluyó 24 preguntas relacionadas con el impacto de la pandemia en diferentes aspectos de la formación y las nuevas estrategias educativas implementadas. Resultados: de 114 alumnos contactados, respondieron 79 (69,3%). Aproximadamente el 90% indicó que su formación se afectó. Un 46% consideró que la práctica médica y la actividad académica se comprometieron por igual y el 45% solo la práctica médica. Un 50% realizó tareas no relacionadas con su formación. El 57% suspendió temporalmente la asistencia a su centro. También informaron una reducción del 55% (DE 18,6) de las actividades relacionadas con la consulta. Conclusiones: la pandemia por SARS-CoV-2 afectó a los estudiantes de Reumatología al limitar sus actividades prácticas y académicas, y por deber realizar tareas ajenas a su formación en más de la mitad de los casos.

Introduction: in 2020, the rapid evolution of the SARS-CoV-2 pandemic triggered a health emergency, generating an important heath system reorganization which led to the discontinuation and subsequent adaptation of training systems. The objective was to describe the pandemic impact on a group of rheumatology trainees in Buenos Aires, Argentina. Materials and methods: an online survey was sent through e-mail to rheumatology specialist course trainees of Argentine Society of Rheumatology and University of Buenos Aires. It included 24 close-ended questions about the pandemic impact on different aspects of rheumatology training and the new implemented educational response strategies. Results: from 114 trainees contacted, 79 (69.3%) responded. Approximately 90% indicated that their rheumatology training was affected. Forty-six percent thought that medical practice and academic activity were equally affected and 45% that only medical practice was compromised. About 50% reported that they had to perform tasks unrelated to their training. Fifty-seven percent discontinued temporarily the training site attendance. Participants reported a mean reduction of 55% (SD 18.6) of activities related to patient care. Conclusions: the SARS-CoV-2 pandemic affected rheumatology trainees, by limiting their practical and academics activities, and having to perform tasks unrelated to their training in more than a half.

Demora en el inicio del tratamiento biológico o sintético dirigido en pacientes con artritis reumatoidea y factores asociados a la misma / Delayed onset of biologic or targeted synthetic dmards in rheumatoid arthritis patients and associated factors

Introducción: el objetivo del tratamiento de la artritis reumatoidea (AR) es la remisión o baja actividad de la enfermedad. En aquellos pacientes que no logran dicho objetivo con drogas modificadoras de la enfermedad sintéticas convencionales (DMARsc), se indican los agentes biológicos (DMARb) o sintéticos dirigidos (DMARsd). El intervalo de tiempo entre la indicación y hasta que el paciente recibe la primera dosis es variable. Objetivos: describir el tiempo de demora y los motivos relacionados entre la indicación de DMARb o DMARsd y la administración de la primera dosis. Materiales y métodos: estudio observacional, analítico, retrospectivo. Se revisaron historias clínicas de pacientes con diagnóstico de AR, a quienes se les indicó DMARb o DMARsd. Se registraron datos sociodemográficos y características de la enfermedad. Respecto de la indicación de DMARb o DMARsd, se consignó: fecha de indicación, fecha en que el paciente recibió la primera dosis en forma efectiva y motivo de la demora. Resultados: se incluyeron 102 pacientes. La mediana de demora desde la indicación de la droga hasta que el paciente recibió la primera dosis fue de 240 días (RIC 113-504). El principal motivo de demora fue de índole burocrática (47%). Los pacientes con baja actividad de la enfermedad obtuvieron la medicación en menor tiempo (113 días) respecto de aquellos con actividad moderada (242 días) y alta actividad (332 días); p=0,01. Los pacientes en los cuales la demora fue por causas burocráticas, presentaron menor nivel de educación (60% vs 17% con educación superior) y residencia en la Provincia de Buenos Aires (58% vs 31% con residencia en la Ciudad Autónoma de Buenos Aires), siendo estas asociaciones estadísticamente significativas. Conclusiones: la mediana en la demora para el inicio de DMARb o DMARsd fue de aproximadamente 8 meses. El motivo principal de este retraso fue de índole burocrática, evidenciándose la misma con mayor frecuencia en aquellos con menor nivel educativo y en los residentes en la Provincia de Buenos Aires.

Introduction: the goal of rheumatoid arthritis (RA) treatment is to obtain remission or low activity of the disease. In those patients who did not achieve this objective with conventional treatment, biologic or targeted synthetic disease-modifying antirheumatic drugs (bDMARD or tsDMARD, respectively) are indicated. The period of time between the prescription of these medications and its administration is variable. Objectives: to describe the delay time between the prescription of a bDMARD or tsDMARD and the administration of the first dose, and its related reasons. Materials and methods: observational, analytical, retrospective study. Medical records of patients with a diagnosis of RA who were prescribed a bDMARD or tsDMARD were reviewed. Sociodemographic data and characteristics of the disease were recorded. Regarding the indication of bDMARDs or tsDMARs, the following data was collected: prescription date, date on which the patient received the first effective dose and reason for the delay. Results: 102 patients were included. The median delay time from the drug prescription until the patient received the first dose was 240 days (IQR 113-504). The main reason for delay was of bureaucratic nature (47%). Patients with low disease activity obtained the medication with a shorter delay (113 days) compared to those with moderate activity (242 days) and high activity (332 days); p=0.01. Patients with a delay related to bureaucratic causes, presented a lower level of education (60% vs 17% with higher education) and residence in the Province of Buenos Aires (58% vs 31% with residence in Autonomous City of Buenos Aires), and these differences were statistically significant. Conclusions: the median delay time to onset of bDMARDs or tsDMARDs was approximately 8 months. The main reason for this delay was of bureaucratic nature, being more frequent in those with lower educational level and residence in the Province of Buenos Aires.

Reticulohistiocitosis multicéntrica: una gran simuladora dentro de la Reumatología / Multicentric reticulohistiocytosis: a great pretender within Rheumatology

La reticulohistiocitosis multicéntrica (RHM) es una histiocitosis de células no Langerhans, multisistémica, rara, caracterizada por afectación cutánea y articular, que poco frecuentemente afecta a otros órganos. El diagnóstico se basa en hallazgos clínicos y resultados de biopsias de piel o sinovial, sin describirse un parámetro de laboratorio específico. Realizamos una revisión de la literatura en relación a las características clínicas de esta entidad desde el punto de vista reumatológico.

Multicentric reticulohistiocytosis (MHR) is a rare, multisystem, non-Langerhans cell histiocytosis characterized by skin and joint involvement, and rarely involving other organs. Diagnosis is based on clinical findings and results of skin or synovial biopsies; a specific laboratory parameter has not been described. We conducted a review of the literature regarding the clinical characteristics of this entity from a rheumatological point of view.

Demora en el inicio del tratamiento biológico o sintético dirigido en pacientes con artritis reumatoidea y factores asociados a la misma / Delayed onset of biologic or targeted synthetic dmards in rheumatoid arthritis patients and associated factors

Introducción: el objetivo del tratamiento de la artritis reumatoidea (AR) es la remisión o baja actividad de la enfermedad. En aquellos pacientes que no logran dicho objetivo con drogas modificadoras de la enfermedad sintéticas convencionales (DMARsc), se indican los agentes biológicos (DMARb) o sintéticos dirigidos (DMARsd). El intervalo de tiempo entre la indicación y hasta que el paciente recibe la primera dosis es variable. Objetivos: describir el tiempo de demora y los motivos relacionados entre la indicación de DMARb o DMARsd y la administración de la primera dosis. Materiales y métodos: estudio observacional, analítico, retrospectivo. Se revisaron historias clínicas de pacientes con diagnóstico de AR, a quienes se les indicó DMARb o DMARsd. Se registraron datos sociodemográficos y características de la enfermedad. Respecto de la indicación de DMARb o DMARsd, se consignó: fecha de indicación, fecha en que el paciente recibió la primera dosis en forma efectiva y motivo de la demora. Resultados: se incluyeron 102 pacientes. La mediana de demora desde la indicación de la droga hasta que el paciente recibió la primera dosis fue de 240 días (RIC 113-504). El principal motivo de demora fue de índole burocrática (47%). Los pacientes con baja actividad de la enfermedad obtuvieron la medicación en menor tiempo (113 días) respecto de aquellos con actividad moderada (242 días) y alta actividad (332 días); p=0,01. Los pacientes en los cuales la demora fue por causas burocráticas, presentaron menor nivel de educación (60% vs 17% con educación superior) y residencia en la Provincia de Buenos Aires (58% vs 31% con residencia en la Ciudad Autónoma de Buenos Aires), siendo estas asociaciones estadísticamente significativas. Conclusiones: la mediana en la demora para el inicio de DMARb o DMARsd fue de aproximadamente 8 meses. El motivo principal de este retraso fue de índole burocrática, evidenciándose la misma con mayor frecuencia en aquellos con menor nivel educativo y en los residentes en la Provincia de Buenos Aires.

Introduction: the goal of rheumatoid arthritis (RA) treatment is to obtain remission or low activity of the disease. In those patients who did not achieve this objective with conventional treatment, biologic or targeted synthetic disease-modifying antirheumatic drugs (bDMARD or tsDMARD, respectively) are indicated. The period of time between the prescription of these medications and its administration is variable. Objectives: to describe the delay time between the prescription of a bDMARD or tsDMARD and the administration of the first dose, and its related reasons. Materials and methods: observational, analytical, retrospective study. Medical records of patients with a diagnosis of RA who were prescribed a bDMARD or tsDMARD were reviewed. Sociodemographic data and characteristics of the disease were recorded. Regarding the indication of bDMARDs or tsDMARs, the following data was collected: prescription date, date on which the patient received the first effective dose and reason for the delay. Results: 102 patients were included. The median delay time from the drug prescription until the patient received the first dose was 240 days (IQR 113-504). The main reason for delay was of bureaucratic nature (47%). Patients with low disease activity obtained the medication with a shorter delay (113 days) compared to those with moderate activity (242 days) and high activity (332 days); p=0.01. Patients with a delay related to bureaucratic causes, presented a lower level of education (60% vs 17% with higher education) and residence in the Province of Buenos Aires (58% vs 31% with residence in Autonomous City of Buenos Aires), and these differences were statistically significant. Conclusions: the median delay time to onset of bDMARDs or tsDMARDs was approximately 8 months. The main reason for this delay was of bureaucratic nature, being more frequent in those with lower educational level and residence in the Province of Buenos Aires.

Reticulohistiocitosis multicéntrica: una gran simuladora dentro de la Reumatología / Multicentric reticulohistiocytosis: a great pretender within Rheumatology

La reticulohistiocitosis multicéntrica (RHM) es una histiocitosis de células no Langerhans, multisistémica, rara, caracterizada por afectación cutánea y articular, que poco frecuentemente afecta a otros órganos. El diagnóstico se basa en hallazgos clínicos y resultados de biopsias de piel o sinovial, sin describirse un parámetro de laboratorio específico. Realizamos una revisión de la literatura en relación a las características clínicas de esta entidad desde el punto de vista reumatológico.

Multicentric reticulohistiocytosis (MHR) is a rare, multisystem, non-Langerhans cell histiocytosis characterized by skin and joint involvement, and rarely involving other organs. Diagnosis is based on clinical findings and results of skin or synovial biopsies; a specific laboratory parameter has not been described. We conducted a review of the literature regarding the clinical characteristics of this entity from a rheumatological point of view.

Validation of the HAQ-UP-A (Health Assessment Questionnaire-Upper Limbs-Argentine Version) in Patients With Rheumatoid Arthritis. / Validación del HAQ-UP-A (Health Assessment Questionnaire-Upper limbs Argentine version) en pacientes con artritis reumatoide.

HAQ is considered the gold standard for the evaluation of functional capacity in patients with rheumatoid arthritis (RA), even though it does not focus on any particular anatomical region. With the objective of assessing functional disability of the hand in elderly patients with osteoarthritis, Baron et al. used a modified version of the HAQ which was calculated as the mean value for the categories mostly involving the upper extremities and named it 'HAQ-UP'. This instrument has not been validated in patients with RA. OBJECTIVE: To validate HAQ-UP-Argentine version in patients with RA. METHODS: Cross-sectional study. Consecutive patients ≥18years with diagnosis of RA (ACR/EULAR 2010) were included. Socio-demographic data and RA characteristics were recorded. Questionnaires were administered: HAQ-A, HAQ-UP-A, FIHOA, Quick-DASH. The reproducibility of the questionnaire was assessed. RESULTS: A total of 100 patients were included, 83% women, mean age 57.9years (SD 11.6). Cronbach's alpha test was 0.94. The intra-item correlation did not show redundant questions. HAQ-UP-A showed excellent correlation with HAQ-A (r=.93); FIHOA (r=.89) and Quick-DASH (r=.91). It also showed good correlation with DAS28-ESR (r=.68) and other composite disease activity indices as well as with other parameters of the disease. There was no correlation between HAQ-UP-A and disease duration. The reproducibility of the questionnaire was 0.82. Multiple linear regression adjusted for age and sex showed patient global VAS as the main determinant of HAQ-UP-A, followed by the presence of morning stiffness. CONCLUSION: HAQ-UP-A was found to be reliable, valid and reproducible in patients with RA, representing a useful tool for the evaluation of the functional capacity of the upper limbs in these patients.

Evaluation of the Educational Needs in Argentine Patients with Rheumatoid Arthritis Using the SpENAT Questionnaire. / Evaluación de las necesidades educacionales de los pacientes con artritis reumatoide mediante el cuestionario SpENAT.

BACKGROUND: The SpENAT, a Spanish version of the Educational Needs Assessment Tool, is a self-completed questionnaire that assesses educational needs (ENs) with the purpose of providing tailored and patient-centered information. It consists of 39 questions grouped into the 7 following domains: Pain management, Movement, Feelings, Arthritic process, Treatments, Self-help measures and Support system. OBJECTIVES: The objective of the study was to describe the ENs of rheumatoid arthritis (RA) patients using the SpENAT and to determine the main sources of information consulted by these patients. MATERIAL AND METHODS: Multicenter, observational, cross-sectional study. We included consecutive patients≥18 years with diagnosis of RA (ACR 87/ACR-EULAR 2010). Sociodemographic data, disease characteristics and clinimetric properties were recorded. All patients completed the SpENAT and were asked about the sources employed to obtain information about their disease. STATISTICAL ANALYSIS: Population characteristics were described. ENs were determined as percentages of the highest possible score for each domain. Needs for each domain according to sex, years of education, disease duration, use of biologicals and functional capacity were analyzed by means of ANOVA, and bivariate comparisons were made with Student's t-test and the Bonferroni correction. Correlation between domains was determined with the Spearman correlation coefficient. We compared patients' age by source of information with Student's t-test. RESULTS: We included 496 patients from 20 centers across the country. More ENs were observed in the domains of Movement, Feelings and the Arthritic process. Patients with higher educational level (>7 years) reported more ENs in the Arthritic process and Self-help measure domains. A higher functional impairment (HAQ-A≥0.87) was associated with more ENs in every domain. Patients with high activity showed more ENs than those in remission in the domains of Pain management, Movement, Feelings, Treatments and Support system, as well as those with low activity in Self-help measures and Support system domains. All SpENAT domains showed positive correlations among each other (P<.0001), the most important being Pain management/Movement and Treatments/Arthritic process (r≥0.7). The source of information most frequently consulted was the rheumatologist (93.95%); those who made use of Internet were on average younger (P=.0004). CONCLUSION: RA patients were very interested about knowing more about their disease. High functional impairment was associated with more ENs. Patients with high disease activity had higher EN levels in almost every domain. The rheumatologist was the main source of information for the patient with RA.